Award
National Cancer Institute 11168890
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)
Recipient
Methodist Hospital Research Institute
Award Amount
$367,053.00
Ceiling
$367,053.00
Awarded
January 16, 2026
Identifier
11168890
A clinical trial funded by the National Cancer Institute to evaluate dual targeting of PI3K/AKT and NOS pathways for treating metaplastic breast cancer, aiming to improve response rate and survival.
Description
The project involves a clinical trial targeting PI3K/AKT and NOS pathways in metastatic MpBC. The project aims to increase objective response rate and survival in metastatic MpBC patients. The study will analyze cell-cell interactions and biomarkers of resistance using spatial transcriptomics and other advanced techniques.